Latest Forum Topics / Biolidics Last:0.014 -- |
![]() |
BIO PHARMA company do research on MEDICAL DISEASES
|
|||||
MakeChanges
Elite |
09-Dec-2021 17:03
![]() Yells: "No price is too low for a bear or too high for a bull" |
||||
x 0
x 0 Alert Admin |
your wish never come true. haha
|
||||
Useful To Me Not Useful To Me | |||||
Starship
Supreme |
09-Dec-2021 13:41
|
||||
x 0
x 0 Alert Admin |
DBS Group Research 09 Dec 2021 PCR Test Providers New saliva ART has the potential to displace PCR testing Singapore has developed a saliva antigen rapid test (ART) that is as accurate as the PCR test The self-administered test has an accuracy of 97% and is able to detect different COVID-19 viral variants, including Omicron The test only takes around 15 minutes, which is the same as the shortest time needed for current ARTs. Current PCR tests can take between a few hours and three days The test kit may be sold in the market in as soon as three months, and we believe that it has the potential to displace the current PCR testing We view this as negative for  Raffles Medical  and  Q & M Dental Group  which currently conduct PCR tests in Singapore Raffles Medical is currently a key PCR test provider at Changi Airport while Q& M also conducts PCR tests but is not involved in on-arrival testing |
||||
Useful To Me Not Useful To Me | |||||
|
|||||
MakeChanges
Elite |
09-Dec-2021 11:07
![]() Yells: "No price is too low for a bear or too high for a bull" |
||||
x 0
x 0 Alert Admin |
then u short now lo. later will gain profit
|
||||
Useful To Me Not Useful To Me | |||||
tofudidi
Supreme |
09-Dec-2021 11:04
|
||||
x 0
x 0 Alert Admin |
1 day wonder. later will crash back to near opening price | ||||
Useful To Me Not Useful To Me | |||||
Joelton
Supreme |
09-Dec-2021 10:11
|
||||
x 0
x 0 Alert Admin |
Biolidics to start producing new Covid-19 Neutralising Antibody Rapid Test Kit by year-end
&bull Biolidics has entered into a definitive manufacturing agreement for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (the " ClearEpi NAB Test" ) and obtained the relevant product liability insurance
 
&bull Unlike most commercially available COVID-19 serology tests which test for IgM/ IgG antibodies in patients, the ClearEpi NAB Test, developed by Biolidics with technology licensed from the Agency for Science, Technology and Research (" A*STAR" )&rsquo s Accelerate Technologies Pte Ltd (&ldquo A*ccelerate&rdquo ), provides results that may indicate an individual' s protective immunity against COVID-19
 
&bull Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
 
&bull The ClearEpi NAB Test can potentially serve as an important tool to assist in the area of assessing vaccine efficacy, vaccine deployment and social activities management (such as air travel2), among others
 
&bull The commercialisation of ClearEpi NAB Test is another Singapore medical technology innovation that showcases the strong collaborative partnerships between Singapore public agencies and the private sector
 
&bull The ClearEpi NAB Test has obtained the CE marking that allows it to be marketed and sold in the European Union
 
Biolidics Limited (&ldquo Biolidics&rdquo or the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ), a medical technology company with a focus on innovative diagnostic solutions, is pleased to announce that it had on 8 December 2021: (i) entered into a definitive agreement with its contract manufacturer for the production of the ClearEpi NAB Test and (ii) obtained the relevant product liability insurance for the ClearEpi NAB Test. The ClearEpi NAB Test was developed by Biolidics with technology licensed from A*STAR&rsquo s A*ccelerate.
 
The commercial production for the ClearEpi NAB Test by the Company is expected to commence in the current financial year ending 31 December 2021.
 
The clinical validation of the ClearEpi NAB Test was undertaken in Singapore. Biolidics engaged A*STAR Infectious Disease Labs (ID Labs) for the screening of the prototype, as part of the clinical validation of the ClearEpi NAB Test conducted by Biolidics. ID Labs is an A*STAR research institute set up in April 2021 to undertake disease-specific research efforts within A*STAR.
 
On 20 September 2021, the Group announced that it has developed the ClearEpi NAB Test that is intended for qualitative detection of neutralising antibodies in serum or plasma which provides an indication of the individual' s protective immunity against COVID-19 infection.
 
Most commercially available serology tests against COVID-19, including the Company&rsquo s COVID-19 Antibody Test Kit launched on 30 March 2020, test for the presence of IgM/IgG antibodies. The presence of IgM/IgG antibodies indicates whether an individual has been previously infected. Not all antibodies have neutralising or &ldquo disarming&rdquo capacity.
 
Neutralising antibodies, on the other hand bind to regions of the virus that &ldquo disarm&rdquo or prevent infection directly. The presence of neutralising antibodies provides indications that an individual has protective immunity against infection1,3. Nonetheless, it is important to note that information is still emerging from researches in relation to the level of antibodies sufficient to confer protective immunity to an individual, and how long such protective immunity against COVID-19 may last in an individual.
 
In addition, the Group announced on 20 September 2021 that it had received confirmation for the CE marking for the ClearEpi NAB Test which enables the Company to market and sell the ClearEpi NAB Test in the European Union.
 
Mr Song Tang Yih (宋 丹 昱 ), Executive Director and Chief Executive Officer of Biolidics, said, &ldquo As the COVID-19 pandemic becomes endemic, we believe that our ClearEpi NAB Test can become a vital tool in assessing vaccine candidates and formulate vaccine deployment strategies (such as the need for additional booster doses).
 
With our ClearEpi NAB Test, the testing of neutralising antibodies may also serve as a guide for government agencies to accelerate the re-opening of the economy, social activities and global travel."
|
||||
Useful To Me Not Useful To Me | |||||
|
|||||
niteowl68
Elite |
09-Dec-2021 10:06
Yells: "God Bleess You" |
||||
x 0
x 0 Alert Admin |
Wow, a quick run to hit 0.21 as within contra period... all out. Must exercise caution as this is a one day or at most two day wonder.  Will wait for the correction b4 re-entry. All huat big.... Dyodd
|
||||
Useful To Me Not Useful To Me | |||||
trademaster
Supreme |
09-Dec-2021 09:49
|
||||
x 0
x 0 Alert Admin |
flush out short term etailers, chart looking gd, 35 ct easy target easywin
|
||||
Useful To Me Not Useful To Me | |||||
easywin
Supreme |
09-Dec-2021 09:41
|
||||
x 0
x 0 Alert Admin |
at 205 / 210 many profit taking liow | ||||
Useful To Me Not Useful To Me | |||||
|
|||||
trademaster
Supreme |
09-Dec-2021 09:40
|
||||
x 0
x 0 Alert Admin |
breakout , should hit all time high 34 ct with such good news | ||||
Useful To Me Not Useful To Me | |||||
MakeChanges
Elite |
09-Dec-2021 09:40
![]() Yells: "No price is too low for a bear or too high for a bull" |
||||
x 0
x 0 Alert Admin |
lets see.... BB playing
|
||||
Useful To Me Not Useful To Me | |||||
Sgvale
Supreme |
09-Dec-2021 09:39
|
||||
x 0
x 0 Alert Admin |
1 day wonder | ||||
Useful To Me Not Useful To Me | |||||
shk363
Master |
09-Dec-2021 09:37
|
||||
x 0
x 0 Alert Admin |
next target 30
|
||||
Useful To Me Not Useful To Me | |||||
|
|||||
easywin
Supreme |
09-Dec-2021 09:36
|
||||
x 0
x 0 Alert Admin |
Price up sustainable?  | ||||
Useful To Me Not Useful To Me | |||||
bobdog
Veteran |
09-Dec-2021 09:35
|
||||
x 0
x 0 Alert Admin |
Those who bought, did you even study it's financial stats? | ||||
Useful To Me Not Useful To Me | |||||
Starship
Supreme |
09-Dec-2021 09:33
|
||||
x 0
x 0 Alert Admin |
![]() ![]() |
||||
Useful To Me Not Useful To Me | |||||
MakeChanges
Elite |
09-Dec-2021 09:28
![]() Yells: "No price is too low for a bear or too high for a bull" |
||||
x 0
x 0 Alert Admin |
why worry? the furture is all about testing testing and testing........
|
||||
Useful To Me Not Useful To Me | |||||
eric998
Supreme |
09-Dec-2021 09:23
|
||||
x 0
x 0 Alert Admin |
Most important is how much money can this bring to the profits?
|
||||
Useful To Me Not Useful To Me | |||||
MakeChanges
Elite |
09-Dec-2021 09:14
![]() Yells: "No price is too low for a bear or too high for a bull" |
||||
x 0
x 0 Alert Admin |
last year this counter  amazingly rose up to 8xx... | ||||
Useful To Me Not Useful To Me | |||||
shk363
Master |
08-Dec-2021 21:23
|
||||
x 0
x 0 Alert Admin |
tomorrow easily clear 20 | ||||
Useful To Me Not Useful To Me | |||||
SmallSmall
Supreme |
08-Dec-2021 21:02
|
||||
x 0
x 0 Alert Admin |
UPDATE ON BIOLIDICS CLEAREPI SARS-COV-2 NEUTRALISING ANTIBODY RAPID TEST KIT &bull Biolidics has entered into a definitive manufacturing agreement for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (the " ClearEpi NAB Test" ) and obtained the relevant product liability insurance &bull Unlike most commercially available COVID-19 serology tests which test for IgM/ IgG antibodies in patients, the ClearEpi NAB Test, developed by Biolidics with technology licensed from the Agency for Science, Technology and Research (" A*STAR" )&rsquo s Accelerate Technologies Pte Ltd (&ldquo A*ccelerate&rdquo ), provides results that may indicate an individual' s protective immunity against COVID-19 &bull Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection1 &bull The ClearEpi NAB Test can potentially serve as an important tool to assist in the area of assessing vaccine efficacy, vaccine deployment and social activities management (such as air travel2), among others &bull The commercialisation of ClearEpi NAB Test is another Singapore medical technology innovation that showcases the strong collaborative partnerships between Singapore public agencies and the private sector &bull The ClearEpi NAB Test has obtained the CE marking that allows it to be marketed and sold in the European Union Singapore, 8 December 2021 &ndash Biolidics Limited  |
||||
Useful To Me Not Useful To Me |